Abbott Completes Exact Sciences Deal, Adds Cologuard, Targets $60 B Cancer Market
Abbott completed its acquisition of Exact Sciences on March 20, 2026, boosting its presence in the $60 billion U.S. cancer screening and precision oncology diagnostics market. It brings noninvasive Cologuard screening, Oncotype DX assays and emerging tests like Oncodetect MRD and Cancerguard, plus a next-generation diagnostics pipeline.
1. Deal Completion and Strategic Positioning
Abbott finalized its purchase of Exact Sciences on March 20, 2026, making Exact Sciences a wholly owned subsidiary. This transaction significantly strengthens Abbott’s diagnostic capabilities and secures a leading position in the U.S. cancer screening and precision oncology diagnostics market valued at about $60 billion.
2. Expanded Product Portfolio
The acquisition integrates Exact Sciences’ flagship offerings—Cologuard, a noninvasive colorectal cancer screening test, and Oncotype DX, a breast cancer treatment decision assay—alongside newer diagnostics like Oncodetect MRD for residual disease monitoring and Cancerguard for multi-cancer detection.
3. Market Impact and Growth Prospects
Abbott anticipates the deal will drive high-single-digit growth in its diagnostics segment by leveraging global commercial scale to expand access to early cancer detection. The combined pipeline of next-generation tests aims to accelerate personalized treatment and ongoing disease monitoring for millions of patients.